- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Sean McLoughlin, GlaxoSmithKline
S
Sean McLoughlin
Product director, diabetes franchise, GlaxoSmithKline
BORN IN: Belfast, Ireland
PEOPLE ARE: "Your long term strategic advantage"
On the tough times ahead:
In five or 10 years, some companies will be here and some will not—and it is the leadership of the company that will determine that. The irony is that it will require a lot of investment in both capital and human resources to be successful at a time when maybe those investments are more likely to drop. It is going to take courage to figure out just what are the key issues, where the company needs to go, and then make those expenditures into the long term health of the company.
Sean McLoughlin
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
